Challenges of Liver Cirrhosis and Tumors: Prevent it, Treat it, Manage Consequences

October 5 – 6, 2012
Congress Center Mainz
Mainz, Germany
12 credit hours (CME) have been awarded for the Falk Symposium 186 by the European Union of Medical Specialists (UEMS) - European Board of Gastroenterology (EBG).
Preface

It is our pleasure to invite you to join the Falk Symposium 186 „Challenges of Liver Cirrhosis and Tumors: Prevent it, Treat it, Manage Consequences“ which will take place in the city of Mainz, Germany.

As stated in the title, we focus on a program merging up-to-date data on pathogenesis of cirrhosis and cancer with relevant topics of clinical practice. Both scientists and clinicians will meet to inspire interdisciplinary discussions on new concepts for the treatment of liver diseases. Top-class scientists and clinicians will present talks on epidemiology and pathogenesis of liver tumors, viral hepatitis and complications of liver cirrhosis. The program is set out to stimulate state of the art discussions about the management of today’s major clinical challenges in hepatology.

We invite you to the city of Mainz, which is traditionally an outstanding location for international meetings in the Rhine-Main area. As capital of the German state of Rhineland-Palatinate, Mainz enjoys a 2,000-year history - from the Romans to the medieval Christian cathedral to modern Germany, a history that is evident throughout the city. Furthermore, Mainz is the home to more than 40,000 students, 4000 scientists, and various academies and scientific facilities thus having been elected ‘City of Science 2011’.

We cordially invite you to participate in this extraordinary meeting and are looking forward to welcoming you in Mainz in October 2012.

Peter R. Galle, Mainz
Challenges of Liver Cirrhosis and Tumors: Prevent it, Treat it, Manage Consequences

Congress Center Mainz
Mainz, Germany

Registration:
Thursday, October 4, 2012
8.00 – 18.00 h
at the congress office

Scientific Organization:
P.-A. Clavien, Zurich (Switzerland)
P. R. Galle, Mainz (Germany)
G. J. Gores, Rochester (USA)
U. Protzer, Munich (Germany)
M. Schuchmann, Mainz (Germany)

Information:
Prof. Dr. Peter R. Galle
Innere Medizin I
Universitätsmedizin der
Johannes Gutenberg-Universität
Langenbeckstr. 1
55131 Mainz
Germany
Telephone: +49 (0)6131/17-7275
Telefax: +49 (0)6131/17-5595
E-mail: galle@mail.uni-mainz.de

Official Language:
English. Simultaneous translation into
German.

Posters:
For details see page 12.
Friday, October 5, 2012

Session I
HCC

Chair: M. Colombo, Milan; M. Peck-Radosavljevic, Vienna

8.00  The size of the problem – Clinical algorithms  
      J. Bruix, Barcelona

8.30  The potential of surveillance – The Japanese experience  
      M. Kudo, Osaka

9.00  Molecular pathogenesis of human liver cancer  
      S. S. Thorgeirsson, Bethesda

9.30  Diagnostic and interventional challenges  
      R. Lencioni, Pisa

10.00  Coffee break with poster session

10.30  Systemic therapy and synergies by combination  
      M.-A. Wörns, Mainz

11.00  HCC: Surgical options  
      P.-A. Clavien, Zurich

11.30  Presentation of the International Hans Popper Award  
      M. P. Manns, Hannover

      Hepatocellular carcinoma: The BCLC approach to clinical and translational research  
      J. Bruix, Barcelona
      J. M. Llovet, Barcelona

12.15  Lunch break with poster session
Friday, October 5, 2012

Session II
Liver Tumors

Chair: G. J. Gores, Rochester; H. Lang, Mainz

13.00 PSC and CC – Pathogenesis and modes of diagnostic C. Schramm, Hamburg

13.30 Liver transplantation for perihilar cholangiocarcinoma G. J. Gores, Rochester

14.00 Liver Adenoma J. Zucman-Rossi, Paris

14.30 Hepatobiliary Malignancies – Lessons from Asia R. Poon, Hong Kong

15.00 Coffee break with poster session

Session III
Viral Hepatitis

Chair: P. R. Galle, Mainz; S. Zeuzem, Frankfurt

HCV

15.30 New insights into the replication cycle of hepatitis C virus R. Bartenschlager, and its interaction with the host cell Heidelberg

16.00 How to treat in 2012 P. Mathurin, Lille

HBV

16.30 Insights in immunology of hepatitis B virus infection U. Protzer, Munich

17.00 Perspectives of future therapy for hepatitis B and D H. Wedemeyer, Hannover
Session IV
Clinical Hepatology
Chair: C. P. Day, Newcastle; M. Schuchmann, Mainz

Controversies 2012: Serum markers or elastometry vs liver biopsy?

8.30 The clinicians’s perspective
L. Castera, Clichy

9.00 The pathologist’s perspective
P. Schirmacher, Heidelberg

9.30 Cholestatic Liver Disease
F. Lammert, Homburg

10.00 Coffee break with poster session

Concepts 2012

10.30 Hemochromatosis
A. Pietrangelo, Modena

11.00 NASH
C. P. Day, Newcastle

11.30 Autoimmune Hepatitis
C. P. Strassburg, Bonn

12.00 Lunch break with poster session
Saturday, October 6, 2012

Clinical Challenges 2012
Chair: A. J. Sanyal, Richmond; D. Schuppan, Mainz

13.00 TIPS for variceal hemorrhage and ascites
A. J. Sanyal, Richmond

13.30 Liver transplantation
G. Otto, Mainz

14.00 Familial amyloid polyneuropathy
A. P. Barreiros, Mainz

14.30 Alcoholic Hepatitis
S. Zakhari, Bethesda

15.00 Antifibrotic therapy – Ready for the clinic?
D. Schuppan, Mainz

15.30 Poster Prize Presentation
P. R. Galle, Mainz
Hans Popper (1903-1988)

Hans POPPER was born 1903 in Vienna where he received his primary and secondary education and started Medical School in 1922. As a student already he was engaged in research in biochemistry, then a quite virgin discipline. Some of his student publications are still quoted today. After graduation in 1928 he continued in pathology and then, in 1933, moved to the famous Department of Internal Medicine at the University of Vienna where he acquired experience with emphasis on renal and hepatic diseases. A promising career was terminated in 1938 by the occupation of Austria. Hans POPPER escaped to the United States and received a research fellowship in Chicago at Cook County Hospital. He started de novo with his own work in the laboratory, had a private practice in gastroenterology, and acquired a Ph.D. in pathology and physiology at the University of Illinois. Within a few years he assembled a hepatic research group leading to the foundation of the Hektoen Institute for Medical Research with POPPER the first director. During World War II he served in the Army, and after return to civilian life, he became the director of pathology Cook County Hospital, Chicago. He did research on all aspects of liver disease and together with Fenton SCHAFFNER he wrote one of the first major English textbooks on the liver, published in 1957, followed by the continuing edition of „Progress in liver diseases“. In the late forties he founded the American Association for the Study of the liver (AASLD); its first meeting taking place in the library of the Hektoen Institute.

From these small beginnings grew the large AASLD of today. Subsequently, he organized with Dame Sheila SHERLOCK the International Association for the Study of the Liver (IASL), which in turn stimulated the creation of many continental and national societies. These, together with the many international symposia of the Falk Foundation, in which Hans POPPER played a leading role, contributed greatly to the establishment of hepatology as a discipline. Although the Chicago years were scientifically most rewarding, Hans POPPER accepted in 1956 the challenging offer to succeed Paul KLEMPERER as pathologist-in-chief at the highly prestigious Mount Sinai Hospital in New York to become professor at Columbia University in New York. Within a few years a new research group with scientists from all over the world assembled at Mount Sinai. Major fields of his scientific interests were cholestasis, the immunology of viral hepatitis, basic mechanisms of cellular and molecular pathology, including communication between liver cells, and hepatic carcinogenesis. The sophisticated research work performed at Mount Sinai Medical School in 1964 with Hans POPPER the founding acting dean. For his Medical School he developed a unique philosophy searching for balance between quantitative molecular biology, attention to social and psychological needs of the patient, and the demands of the community at large. Hans POPPER combined the chairmanship of pathology, the leadership of the liver unit with the deanship of academic affairs until 1971, when he retired as chairman of the pathology department, but remained as Gustave L. Levy Distinguished Service Professor.

After his retirement he became a Foqarty Scholar at the National Institutes of Health in Bethesda and began cooperations with several laboratories and universities, particularly in the field of viral hepatitis and liver carcinogenesis. He called himself a Traveller in Academic Affairs. With unrelenting enthusiasm and inexhaustible energy in this 8th decade he acquired competence in the modern technology of molecular and cellular biology. The hepatologic community greatly benefited from his inspiring scientific contributions (almost 800 publications and 23 books), and his critical judgement and stimulating discussions at meetings until a few weeks before his death on May 6, 1988 at the age of 85. His merits have been honored by memberships in four major academies, including the National Academy of Sciences USA, 14 honorary doctorates, many medals and prizes,
and honorary memberships or presidencies of national and international societies. Last but not least the laboratories at Mount Sinai School of Medicine, New York, and at the Department of Pathology of the University of Vienna are named after him. He has left us a rich heritage and we can only aspire to follow in his footsteps.

Leonardo Bianchi

**International Hans Popper Award 2012**

The International Hans Popper Award was created by the Falk Foundation e.V. and will be presented for the seventh time on the occasion of the Falk Symposium 186 on October 5, 2012. The prize will be endowed with € 25.000,-. It is awarded for outstanding contributors to basic and experimental hepatology, including molecular genetics, molecular biology, physiology, biochemistry and pathology of acute and chronic liver diseases and its sequelae.

**Members of the Prize Committee:**

- M. Colombo, Mailand (Italy)
- M. Trauner, Vienna (Austria)
- M. Houghton, San Francisco (USA)
- M. Omata, Hongo (Tokyo)
- P. Ginès, Barcelona (Spain)
- R. Perrillo, Dallas (USA)

**Hans Popper Award Winners 1989 - 2012:**

- 1989 - H.C. Thomas, London (Great Britain)
- 1992 - M. Rizzetto, Turin (Italy)
- 1995 - M. P. Manns, Hannover (Germany)
- 1999 - M. Houghton, Emeryville (USA)
- 2003 - S. L. Friedmann, New York (USA)
- 2006 - P. Ginès, Barcelona (Spain)
- 2012 - J. Bruix, Barcelona (Spain) / J. M. Llovet, Barcelona (Spain)

**Coordinator of the Hans Popper Award Committee:**

Prof. Dr. Michael P. Manns
Klinik für Gastroenterologie
Medizinische Hochschule Hannover
Carl-Neuberg-Str. 1
30625 Hannover
Germany
**Poster Session**

Posters will be exhibited on October 5 – 6, 2012, at the Congress Center Mainz. The authors will be in attendance during coffee and lunch breaks on both days.

1. Diagnostic and predictive value of some tumor markers in the diagnosis and follow up of patients with hepatocellular carcinoma
   G. Abdel-Aleem, A. Wagih, M. Abel-Azem, S. Abousaif, M. Sharaf-Eldin (Tanta, EG)

2. Nutritional status in various etiology cirrhosis
   E.I. Adamenka, N.N. Silivontchik (Minsk, RU)

3. Hematologic and hepatic abnormality in HCV+ patients with B NLH
   D. Badea, M. Badea, A. Genunche-Dumitrescu, A. Badea (Craiova, RO)

4. HVC infections and B lymphoma
   M. Badea, D. Badea, A. Genunche-Dumitrescu, A. Badea, D. Duta (Craiova, RO)

5. Assessing internet environment influence on hepatology understanding
   F. Battisti, M. Carli, M. Delle Monache (Rome, IT)

6. The value of echo guided liver biopsy in the positive diagnosis of a rare primary liver tumour- pathological approach
   G. Becheanu, V. Herlea, V. Serban-Barbu, M. Dumbrava, S. Enache, G. Smira, C. Angelescu, A. Pop, M. Diculescu (Bucharest, RO)

7. Endotoxemia associated with neutropenia during antiviral therapy of chronic hepatitis C virus infection with severe fibrosis
   E. Bondarenko, N. Geyvandova, A. Yagoda (Stavropol, RU)

8. Effect of pituitary tumor-transforming gene on progression of liver fibrosis
   V. Buko, E. Belanovskaya, O. Lukivskaya, E.E. Naruta, O. Zhuk (Grodno, BY)

9. Comparison of chronic hepatitis B patients using Tenofovir and Entecavir in terms of viral kinetics, virologic response and side effects
   B. Ceylan, M. Fincanci, C. Muderrisoglu, F. Soysal, G. Eren, M. Basaranoglu (Istanbul, TR)

10. Treatment with UDCA and neuroendocrine tumor
    C. Cimpoeru (Bucharest, RO)

11. Prevalence and risk factors for liver involvement in individuals with PiZZ-related lung disease
    M.F. Dawwas, S.E. Davies, W.J. Griffiths, D.A. Lomas, G.J. Alexander (Nottingham, London, GB)
12. Diabete mellitus-type 2 and chronic hepatitis B-metabolic changes
   C. Deliu, D. Neagoe, L. Bobea, C. Hoanca, S. Enculescu (Craiova, RO)

13. Incidence of diabetes mellitus, obesity and cardiovascular changes in hepatic steatosis
   C. Deliu, D. Neagoe, S. Enculescu, C. Hoanca, L. Bobea (Craiova, RO)

14. A combined algorithm for non-invasive diagnosis of liver cirrhosis
   M. Delle Monache, R. Cecere, C. Francia, L. Baiocchi, I. Lenci, F. De Leonardis (Rome, IT)

15. The study of predictive factors concerning the risk of renal complications of chronic ascitis
   A.O. Docea, P. Mitrut, D. Calina, E. Gofita, A. Genunche-Dumitrescu, R. Mitrut, D. Salplahta (Craiova, RO)

16. Can faecal calprotectin predict the spontaneous bacterial peritonitis in cirrhosis
   M. Dranga, M. Badea, I. Pintilie, N. Otilia, C. Mihai (Iasi, RO)

17. Patterns of decompensation in patients with non-alcoholic cirrhosis vs. alcoholic cirrhosis
   G. Dumitrescu, I. Pintilie, N. Otilia, M. Badea, A. Blaj, C. Cijevschi Prelipcean (Iasi, RO)

18. Liver fibrosis may reduce the efficacy of budesonide in the treatment of autoimmune hepatitis and overlap syndrome
   C. Efe, E. Ozaslan, T. Kav, T. Purnak, A. Shorbagi, O. Ozkayar, A.H. Berlot, C. Sökmensuer, P. Muratori (Ankara, TR; Reims, FR; Bologna, IT)

19. Diagnosis of hepatomegaly always a surprise
   M. Enache, M. Sotcan, C. Jurcut (Bucharest, RO)

20. Portal vein thrombosis pour prognostic factor in cirrhotic patients
   M. Enache, M. Sotcan, C. Jurcut (Bucharest, RO)

21. Correlation between Hamaguchi score, insulin resistance and fatty liver indexes in adult patients affected by non alcoholic fatty liver disease
   C. Francia, R. Cecere, L. Baiocchi, I. Lenci, F. De Leonardis, M. Delle Monache (Rome, IT)

22. Liver cancer in HBV cirrhosis and prolonged antiviral treatment - 20 year observation - A clinical case
   D. Gancheva, I. Kotzev (Varna, BG)
23. Combined therapy for primary biliary cirrhosis after suboptimal response to UDCA monotherapy
   A. Genunche-Dumitrescu, M. Badea, D. Badea, P. Mitrut, A. Badea (Craiova, RO)

24. Contribution of non-viral risk factors to development of hepatocellular carcinoma
   A. Genunche-Dumitrescu, D. Badea, M. Badea, P. Mitrut (Craiova, RO)

25. Effect of alcohol consumption on the progression of hepatitis C virus infection and risk to develop hepatocellular carcinoma
   A. Genunche-Dumitrescu, D. Badea, M. Badea, P. Mitrut (Craiova, RO)

26. Anticoagulation therapy in cirrhotic patients with nonmalignant portal vein thrombosis
   L. Gheorghe, S. Iacob, R. Cerban, D. Coriu, C. Gheorghe (Bucharest, RO)

27. Efficacy and safety of triple therapy in clinical practice
   L. Gheorghe, I. Simionov, L. Tugui, M. Diculescu, C. Cotruta, D. Coriu (Bucharest, RO)

28. Hepatocellular carcinoma: Aspects of management at two tertiary centers in Romania
   L. Gheorghe, S. Iacob, C. Ghidu, R. Iacob, C. Gheorghe, I. Simionov, I. Sporea, M. Danila, A. Croitoru, M. Croitoru, D. Hrehoret, I. Popescu (Bucharest, Timisoara, RO)

29. Does IL28 genotype variability influence the EVR in HCV patients?
   A. Goldis, R. Goldis, L. Olaru, I. Ratiu, D. Lazar (Timisoara, RO)

30. Upper gastrointestinal bleeding in liver cirrhosis - prognostic factors
   R. Goldis, A. Goldis, V. Lungu (Timisoara, RO)

31. Extremely low vitamin D levels are associated with increased mortality in patients with liver cirrhosis
   F. Grünhage, M. Krawczyk, C. Stokes, M. Langhirt, C. Reichel, F. Lammert (Homburg, Bad Brückenau, DE)

32. Increased numbers of CD4+, CD8+ and FOXP3+ immune cells in malignant and benign liver tumors
   M. Gulubova, K. Ivanova, J. Ananiev, I. Manolova (Stara Zagora, BG)

33. Accuracy of ARFI to predict stage of liver fibrosis in patients with liver diseases
   V. Hejda, H. Mirka, V. Skala, J. Kozeluhova (Pilsen, CZ)

34. Quantitative gene expression of liver enriched transcription factors in curatively treated hepatocellular carcinoma
35. Follow-up and predictors of graft outcome in recurrent hepatitis C post-liver transplantation
   S. Iacob, D. Hrehoret, E. Matei, B. Dorobantu, V. Brasoveanu, M. Dumbrava, G. Becheanu, V. Herlea, I. Popescu, L. Gheorghe (Bucharest, RO)

36. Cardiovascular risk in patients with nonalcoholic fatty liver disease with and without newly diagnosed diabetes mellitus type 2
   R. Ivanova, A. Alexiev, S. Denchev, R. Ivanova, L. Mateva (Sofia, BG)

37. Natural fluctuations of serum HBsAg level in HBeAg-negative chronic hepatitis B
   D. Jelev, K. Antonov, A. Ivanova, L. Mateva, Z. Krastev (Sofia, BG)

38. Radical or conservative surgery for hydatidosis of the liver and effects of the residual liver parenchyma: 30 years multicentric experience
   K. Kalinova, A. Karachmalakov, P. Stefanova (Stara Zagora, BG)

39. Alternative treatment of hepatitis B and C by phosphogliv when Interferon cannot be used
   A. Khidasheli, N. Rukhadze (Tbilisi, GE)

40. Manifestations and complications of liver cirrhosis: Role of mediators of intercellular interactions
   P.V. Koroy, A. Yagoda, I.S. Mukhoramova, G.I. Gilyazova (Stavropol, RU)

41. Hyaluronic acid - Age related liver fibrotic marker
   O. Kosseva, S. Bocheva, D. Jelev, K. Antonov, Z. Krastev (Sofia, BG)

42. Autoimmune hepatits (AIH) and celiac disease in two-year-old child: Diagnosis and therapy
   A. Lavrova (Nizhny Novgorod, RU)

43. Long-term outcomes following drug-eluting bead transarterial chemoembolisation (DEB-TACE) as part of multimodality treatment for hepatocellular carcinoma
   C. Lever, P. Kumar, S. George, N. Hacking, B. Stedman, T. Bryant, D. Breen, M. Wright (Southampton, GB)

44. Fetal hemoglobin in liver cirrhosis with pulmonary hypertension
   B. Levitan, T. Kasianova, Y. Levitan (Astrakhan, RU)

45. The lipopolysaccharide binding protein plasma concentration in liver cirrhosis
   B. Levitan, T. Kasianova, O. Voloshina, G. Levitan (Astrakhan, RU)

46. Mitochondrial abnormalities in nonalcoholic steatohepatitis in pediatric patients
   J.M. Lotowska, M.E. Sobaniec-Lotowska, U. Sulikowska, D.M. Lebensztejn (Bialystok, PL)
47. Prophylactic therapy with nor-ursodeoxycholic acid in experimental thioacetamide-induced liver fibrosis
   O. Lukivskaya, E. Naruta, E. Belanovskaya, V. Abakumov, V. Buco (Grodno, BY)

48. Hepatocellular carcinoma: Risk factors of carcinogenesis, carcinogenesis rate
   G. Minzala, L. Iliescu, A. Martiniuc, M. Voiculescu (Bucharest, RO)

49. The efficacy of mesalazine therapy (Salofalk tablets) in spondylarthropathies
   P. Mitrut, A.O. Docea, A. Enescu, A. Genunche-Dumitrescu, D. Badea, D. Salplahta (Craiova, RO)

50. The role of HLA complex genes in non-alcoholic fatty liver disease
   D. Neagoe, A. Amzolini, G. Ianosi, M. Dutescu, S. Ianosi, T. Ciurea (Craiova, Bucharest, RO)

51. The relationship between bone mineral density and liver cirrhosis in postmenopausal women
   D. Neagoe, G. Ianosi, A. Genunche-Dumitrescu, M. Bezna (Craiova, RO)

52. RVR in chronic hepatitis C patients on standard bi-therapy
   N. Nikolova, D. Jelev, K. Antonov, A. Ivanova, L. Mateva, Z. Krastev (Sofia, BG)

53. Natural course of HCV RNA. The paradigm of 5 logs?
   N. Nikolova, K. Antonov, D. Jelev, A. Ivanova, L. Mateva, Z. Krastev (Sofia, BG)

54. Hepatitis C-associated hepatocellular carcinoma in an african woman with non-cirrhotic liver
   L. Nosotti (Rome, IT)

55. Treatment of chronic viral hepatitis B and C in patients with inflammatory bowel disease

56. Liver steatosis and iron overload
   M. Penkova, M.V. Gulubova, J. Ananiev, R. Ivanova, L. Mateva-Vladimirova (Stara Zagora, Sofia, BG)

57. Analysis of the notch signaling pathway in cholangiocarcinoma cell lines

58. Serum TWEAK levels: To explain the mechanisms of development of nonalcoholic fatty liver disease
59. Terlipressin infusion harmonize the hepatic and renal blood flow assessed by doppler ultrasonography
   D. Popov, L. Mateva, Z. Krastev (Sofia, BG)

60. Effect of hypochromic anemia on the course of chronic liver injuries in children
   N.V. Pronko (Grodno, BY)

61. Studies on hepatoprotective activities of calcium folinate and betaine in rats with chronic alcohol intoxication
   P.S. Pronko, T.I. Khomich, V.I. Satanovskaya, R.E. Lis (Grodno, BY)

62. HBV and alcohol consume
   M. Pumnea, E.C. Rezi, R.G. Mihaila, L. Nedelcu (Sibiu, Brasov, RO)

63. Comparison with Maddrey discriminant function, model for end-stage liver disease and Child-Turcotte-Pugh scores for predicting mortality in patients with alcoholic hepatitis
   S. Raicevic Sibinovic, A. Nagorni, M. Radisavljevic, V. Brzacki (Nis, RS)

64. Treating hyponatremia in hepatic cirrhosis: Are we forgetting something very important?
   I. Rankovic, D. Popovic, D. Culafic, M. Stojkovic, M. Krstic, Z. Rajic, P. Pesko, T. Milosavljevic (Belgrade, RS)

65. Study regarding alcohol consumption in patients with chronic viral C hepatitis
   E.C. Rezi, M. Pumnea, R.G. Mihaila, L. Nedelcu (Sibiu, Brasov, RO)

66. Distribution of hepatitis C virus genotypes in Georgia and treatment of Peginterferon alpha-2 (40KD) and Ribavirin
   N. Rukhadze, M.T. Zhamutashvili, M. Shatberashvili (Tbilisi, GE)

67. Risk Factors for recurrence of hepatocellular carcinoma (HCC) after radiofrequency ablation (RFA) in a cohort of egypytian patients with HCV-induced cirrhosis: A multi-center analysis
   M. Sharaf-Eldin, S. El-yamany, E. Habba, M. Shaker, M. Kohla, H. Abdel-Fattah (Tanta, Cairo, EG)

68. Hepatic encephalopathy in alcoholic hepatitis
   N.N. Silivontchik, E.I. Adamenka (Minsk, BY)

69. The circulating levels of matrix metalloproteinase-9 (MMP-9) and tissue inhibitor of metalloproteinase 1 (TIMP-1) in chronic hepatitis C
   C.A. Silosi, I. Silosi, V. Biciusca, M. Cojocaru, M. Cojocaru (Craiova, RO)
70. The diagnostic and prognostic value of associated autoantibodies to primary biliary cirrhosis
   I. Silosi, C.A. Silosi, M. Cojocaru, V. Biciusca, M. Cojocaru (Craiova, Bucharest, RO)

71. Influence of triple therapy on nutritional status of patients with chronic hepatitis C
   I. Simionov, L. Gheorghe (Bucharest, RO)

72. Clinicopathological features and outcome of autoimmune hepatitis/primary sclerosing cholangitis overlap syndrome
   I. Simionov, L. Gheorghe, C. Gheorghe (Bucharest, RO)

73. The decreasing of the liver detoxic function in chronic hepatitis and liver cirrhosis patients and the ways of it’s pharmacological correction
   I.N. Skrypnyk, G. Maslova (Poltava, UA)

74. Adult living donor liver transplantation - 8 year donor safety experience
   G. Smira, S. Iacob, C. Gheorghe, I. Popescu, L. Gheorghe (Bucharest, RO)

75. Morphological exponents of fibroductular reaction in the model of experimental secondary biliary fibrosis induced by bile duct ligation in young rats. A preliminary report
   M.E. Sobaniec-Lotowska, J.M. Lotowska, D.M. Lebensztejn, W. Debek (Bialystok, PL)

76. Transarterial chemoembolization and Sorafenib combined therapy in patient with advanced hepatocellular carcinoma
   B. Tomov, J. Todorov, V. Velchev, L. Mateva (Sofia, BG)

77. Some parameters of iron and copper metabolism in patients with hereditary haemochromatosis
   L. Turecky, V. Kupcova, E. Uhlikova, J. Netriova, P. Bozek (Bratislava, SK)

78. Markers of oxidative stress in patients with Wilson’s disease
   L. Turecky, V. Kupcova, M. Kolacek, J. Muchova, E. Uhlikova (Bratislava, SK)

79. Some parameters of oxidative stress in patients with hereditary haemochromatosis
   E. Uhlikova, V. Kupcova, J. Muchova, M. Kolacek, L. Turecky (Bratislava, SK)

80. Ceruloplasmin and its enzymatic activity in patients with Wilson’s disease
   E. Uhlikova, V. Kupcova, L. Turecky (Bratislava, SK)

81. Rifaximin treatment in hepatic encephalopathy - A single centre experience
   T. Valliani, M. Sumner, F. Gordon (Bristol, GB)
82. The NPCL1 inhibitor ezetimibe improves metabolic disease via decreased LXR activity  
M. Watanabe, T. Sugizaki (Tokyo, JP)

83. Relationship between immunoglobulins superfamily parameters and histologic changes in chronic viral liver diseases  
A. Yagoda, P.V. Koroy, I.S. Mukhoramova, G.I. Gilyazova (Stavropol, RU)

84. Gallstones associated with nonalcoholicsteatohepatosis  
O. Yener (Istanbul, TR)

85. The alcoholic liver lesion estimated by duplex-doppler sonography  
J. Zabielska, M. Olszewska-Banaszczyk, G. Zabielski, A. Bala (Lódz, PL)

86. The hepatic lesion in metabolic syndrom patients - Assessment by duplex-doppler sonography  
G. Zabielski, M. Broncel, J. Zabielska, K. Wojdan (Lódz, PL)

87. Early on-treatment response as a predictor of sustained virological response in genotype 4 HCV naive egyptian patients treated with Peginterferon plus Ribavirin  
List of Speakers, Moderators and Scientific Organizers

PD Dr. Ana Paula Barreiros
Innere Medizin I
Klinikum der Universität
Langenbeckstraße 1
55131 Mainz
Germany
barreiro@uni-mainz.de

Prof. Dr. Ralf Bartenschlager
Molekulare Virologie
Universitätsklinikum Heidelberg
Im Neuenheimer Feld 324
69120 Heidelberg
Germany
ralf.bartenschlager@med.uni-heidelberg.de

Prof. Dr. Jordi Bruix
Hospital Clínico y Provincial
Universidad de Barcelona
BCLC Group
c/Villaroel no. 170
08036 Barcelona
Spain
jbruix@clinic.ub.es

Dr. Laurent Castera
Service c’Hépatologie
Hôpital Beaujon
Université Denis Diderot Paris 7
100 bolevard du Général Leclerc
92110 Clichy
France
laurent.castera@bjn.aphp.fr

Prof. Dr. Pierre-Alain Clavien
Universitätsspital Zürich
Visceralchirurgie
Rämistrasse 100
8091 Zürich
Switzerland
clavien@access.uzh.ch

Prof. Dr. Massimo Colombo
Ospedale Maggiore
IRCCS Policlinico
Dipartimento di Gastroenterologia
ed Encrinologia
Via Francesco Sforza, 35
20122 Milano
Italy
massimo.colombo@unimi.it

Prof. Dr. Christopher P. Day
University of Newcastle
The Medical School
Center for Liver Research
William Leech Building
Framlington Place
Newcastle-Upon-Tyne NE2 4HH
Great Britain
c.p.day@ncl.ac.uk

Prof. Dr. Peter R. Galle
Innere Medizin I
Universitätsmedizin der
Johannes Gutenberg-Universität
Langenbeckstr. 1
55131 Mainz
Germany
galle@mail.uni-mainz.de

Gregory J. Gores, M.D.
Mayo Clinic
Division of Gastroenterology & Hepatology
200 First Street SW
Rochester MN 55905
USA
gores.gregory@mayo.edu

Dr. Masatoshi Kudo
Kinki University
School of Medicine
Div. of Gastroenterology
Dep. of Internal Medicine
Osakasayama
Osaka 589-0000
Japan
m-kudo@med.kindai.ac.jp
Prof. Dr. Peter Schirmacher  
Pathologie  
Universitätsklinikum Heidelberg  
Im Neuenheimer Feld 220/221  
69120 Heidelberg  
Germany  
peter.schirmacher@med.uni-heidelberg.de

Prof. Dr. Christoph Schramm  
Medizinische Klinik I  
Universitätsklinikum Eppendorf  
Martinistraße 52  
20251 Hamburg  
Germany  
cschramm@uke.de

Prof. Dr. Marcus Schuchmann  
Innere Medizin I  
Universitätsmedizin der  
Johannes Gutenberg-Universität  
Langenbeckstraße 1  
55131 Mainz  
Germany  
marcus.schuchmann@unimedizin-mainz.de

Prof. Dr. Dr. Detlef Schuppan  
Innere Medizin I  
Universitätsmedizin der  
Johannes Gutenberg-Universität  
Langenbeckstraße 1  
55131 Mainz  
Germany  
detlef.schuppan@unimedizin-mainz.de

Prof. Dr. Christian P. Strassburg  
Medizinische Klinik I  
Universitätsklinikum Bonn  
Sigmund-Freud-Str. 25  
53127 Bonn  
Germany  
christian.strassburg@ukb.uni-bonn.de

Snorri S. Thorgeirsson, M.D. PhD  
National Institutes of Health  
NCI, NIH, MSC 4262  
Lab. Of Experimental Carcinogene  
37 Convent Drive  
Bethesda MD 20892  
USA  
thorgeis@mail.nih.gov

Prof. Dr. Heiner Wedemeyer  
Klinik für Gastroenterologie,  
Hepatologie und Endokrinologie  
Medizinische Hochschule Hannover  
Carl-Neuberg-Str. 1  
30625 Hannover  
Germany  
wedemeyer.heiner@mh-hannover.de

Dr. Marcus-A. Wörns  
Innere Medizin I  
Universitätsmedizin der  
Johannes Gutenberg-Universität  
Langenbeckstraße 1  
55131 Mainz  
Germany  
woerns@uni-mainz.de

Samir Zakhari, PhD  
National Institute on Alcohol  
Abuse and Alcoholism  
Division of Metabolism & Health Effects  
5635 Fishers Lane, MSC 9340  
Bethesda MD 20892  
USA  
szakhari@mail.nih.gov

Prof. Dr. Stefan Zeuzem  
Innere Medizin I  
Klinikum der Johann Wolfgang  
Goethe-Universität Frankfurt  
Theodor-Stern-Kai 7  
60596 Frankfurt  
Germany  
stefan.zeuzem@kgu.de

Dr. Jessica Zucman-Rossi  
Inserm, U674  
Génomique fonctionnelle des tumeurs solides  
27 rue Juliette Dodu  
Paris 75010  
France  
jessica@inserm-u674.net
Congress Office

During Falk Symposium 186

Telephone: +49 (0)175/7795327

Congress Center Mainz
Rheinstr. 66
55116 Mainz
Germany

Opening Hours:
Tuesday, October 2, 2012  16.00 – 21.00 h
Wednesday, October 3, 2012  7.30 – 18.00 h
Thursday, October 4, 2012  8.00 – 18.00 h
Friday, October 5, 2012  7.30 – 17.30 h
Saturday, October 6, 2012  8.00 – 16.30 h

Congress Fees

Scientific program of the Falk Symposium 186  € 200,—
Students and residents  € 100,—

* * * OR * * *

Day ticket  € 120,—
Students and residents  € 60,—

The congress fees include:
- Refreshments during coffee breaks
- Lunch on October 5 and 6, 2012
- A copy of the abstract volume

Admission to Scientific Events

For admission to scientific events your name badge should be clearly visible.
Congress Report
The official congress report of the Falk Symposium 186 “Challenges of Liver Cirrhosis and Tumors: Prevent it, Treat it, Manage Consequences” will be published in English in the first half of 2013 by Karger Publishers, Basel, Switzerland. Orders for this book at a reduced subscription price of € 35,- can be placed at the Congress Office during the congress in Mainz.

Airport
International Airport Frankfurt
Innovative Drugs
for bowel and liver diseases
Modern formulations and specially designed delivery systems ensure targeted release of the active drug

Scientific Dialogue
in the interest of therapeutic progress
Falk Symposia and Workshops
nearly 250, attended by more than 100,000 participants from over 100 countries since 1967
Continuing medical education seminars
over 14,000, attended by more than one million physicians and patients in Germany alone
Comprehensive literature service for healthcare professionals and patients
with more than 200 publications

www.falkfoundation.org  www.drfalkpharma.com
Leinenweberstr. 5 79108 Freiburg Germany  Tel +49 (0)761/1514-0  Fax +49 (0)761/1514-321  Mail zentrale@drfalkpharma.de
Falk Symposium    186

Challenges of Liver Cirrhosis and Tumors: Prevent it, Treat it, Manage Consequences

October 5 – 6, 2012
Congress Center Mainz
Mainz, Germany

Program